Indaptus Therapeutics details board and COO changes

Indaptus Therapeutics, Inc. reported several leadership changes.

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. reported several leadership changes. Effective June 5, 2026, directors David E. Lazar and Avraham Ben-Tzvi resigned from all positions on the Board of Directors, including all committee roles. Effective June 1, 2026, Walt A. Linscott, Esq. resigned as Chief Operating Officer.

Linscott entered into a consulting agreement dated June 1, 2026 and will continue serving the company as a consultant in a strategic advisory role. The company stated that the resignations of Lazar, Ben-Tzvi, and Linscott were not the result of any disagreement with Indaptus on operations, policies, or practices.

Insights

Corporate governance analyst

Indaptus reports multiple leadership changes framed as non‑contentious.

Indaptus Therapeutics disclosed the resignations of two directors and its Chief Operating Officer, with the COO transitioning into a consulting role under an agreement dated June 1, 2026. The company explicitly states there were no disagreements over operations, policies, or practices.

Board turnover and an executive change can matter for strategic continuity, but retaining Walt Linscott as a consultant suggests some preservation of institutional knowledge. The filing does not tie these changes to any financial metrics or strategic shifts, so the information is notable but not clearly thesis‑altering on its own.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Board of Directors, Chief Operating Officer, consulting agreement, Emerging growth company

4 terms

Board of Directors financial

"resigned from all directorship positions, including from all committees served, on the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Chief Operating Officer financial

"Effective as of June 1, 2026, Mr. Walt A. Linscott, Esq. resigned as the Chief Operating Officer"

A chief operating officer (COO) is a senior executive responsible for overseeing the day-to-day activities of a company, ensuring that all parts of the organization work smoothly and efficiently. They often act like a company's operational quarterback, translating strategic plans into practical actions. For investors, the COO's effectiveness can influence a company's performance and stability, making them an important figure in assessing the company's management strength.

consulting agreement financial

"pursuant to a consulting agreement with the Company dated June 1, 2026, will serve as a consultant"

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership changes did Indaptus Therapeutics (INDP) announce in this 8-K?

Indaptus Therapeutics disclosed that directors David E. Lazar and Avraham Ben-Tzvi resigned from all Board and committee roles, and Chief Operating Officer Walt A. Linscott resigned his officer position but will remain with the company as a consultant under a new agreement.

When are the director and COO resignations at Indaptus Therapeutics (INDP) effective?

The company reported that the resignations of directors David E. Lazar and Avraham Ben-Tzvi are effective June 5, 2026, while Chief Operating Officer Walt A. Linscott’s resignation became effective June 1, 2026, coinciding with the start of his consulting role.

Did the departing directors or COO report any disagreements with Indaptus Therapeutics (INDP)?

Indaptus Therapeutics stated that the resignations of David E. Lazar, Avraham Ben-Tzvi, and Walt A. Linscott were not due to any disagreement with the company on matters relating to its operations, policies, or practices, indicating the departures are not described as conflict-driven.

What role will former COO Walt A. Linscott have at Indaptus Therapeutics (INDP) going forward?

Following his resignation as Chief Operating Officer effective June 1, 2026, Walt A. Linscott will continue with Indaptus Therapeutics as a consultant under a consulting agreement dated June 1, 2026, providing strategic advisory services to the company.

Which SEC form did Indaptus Therapeutics (INDP) use to report these leadership changes?

Indaptus Therapeutics reported the resignations of two directors and its Chief Operating Officer on a Form 8-K, using Item 5.02, which covers departures and appointments of directors or certain officers and related compensatory arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:30 PM Learn about SEC filing dates

false 0001857044 0001857044 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2026

INDAPTUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40652		86-3158720
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3 Columbus Circle 15th Floor New York, New York		10019
(Address of principal executive offices)		(Zip Code)

(646) 427-2727

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		INDP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Directors and Officer

Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”).

Effective as of June 1, 2026, Mr. Walt A. Linscott, Esq. resigned as the Chief Operating Officer of the Company, and, pursuant to a consulting agreement with the Company dated June 1, 2026, will serve as a consultant for the Company.

Mr. Lazar’s, Mr. Ben-Tzvi’s and Mr. Linscott’s resignation was not a result of any disagreement with the Company on any matter relating to its operations, policies or practices. The Board wishes to thank Mr. Lazar and Mr. Ben-Tzvi for their services and contributions to the Company, and looks forward to continuing to work with Mr. Linscott in his strategic advisory role.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 5, 2026

	INDAPTUS THERAPEUTICS, INC.
	By:	/s/ Junyi Dai
	Name:	Junyi Dai
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB